Arsanis’s Series B Adds $20M to Move Staph Drug into Clinic
LONDON – Arsanis Inc. has raised $20 million in Series B funding that will enable the Austro-American company to take its lead monoclonal antibody product, ASN-100, through Phase I/IIa development in the treatment of severe, hospital-acquired Staphylococcus aureus infections.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter